Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
Public ClinicalTrials.gov record NCT00256854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients With Restless Legs Syndrome (RLS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.
Study identification
- NCT ID
- NCT00256854
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 135 participants
Conditions and interventions
Interventions
- Ropinirole IR 1 mg Drug
- Ropinirole IR 2 mg Drug
- Ropinirole IR 1 mg Placebo Drug
- Ropinirole IR 2 mg Placebo Drug
- Ropinirole CR 2 mg Drug
- Ropinirole CR 3 mg Drug
- Ropinirole CR 2 mg Placebo Drug
- Ropinirole CR 3 mg Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2005 (Actual)
- Primary completion
- Sep 21, 2006 (Actual)
- Completion
- Sep 21, 2006 (Actual)
- Last update posted
- Mar 15, 2019
2005 – 2006
United States locations
- U.S. sites
- 30
- U.S. states
- 20
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Laguna Hills | California | 82653 | — |
| GSK Investigational Site | Oxnard | California | 93030 | — |
| GSK Investigational Site | Pasadena | California | 91106 | — |
| GSK Investigational Site | Reseda | California | 91355 | — |
| GSK Investigational Site | Boca Raton | Florida | 33486 | — |
| GSK Investigational Site | St. Petersburg | Florida | 33701 | — |
| GSK Investigational Site | Tampa | Florida | 33609 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Oak Brook | Illinois | 60523 | — |
| GSK Investigational Site | Lenexa | Kansas | 66214 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| GSK Investigational Site | Springfield | Massachusetts | 01104 | — |
| GSK Investigational Site | Bingham Farms | Michigan | 48025 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89119 | — |
| GSK Investigational Site | Lebanon | New Hampshire | 03766 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 08003 | — |
| GSK Investigational Site | Toms River | New Jersey | 08755 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | Plainview | New York | 11803 | — |
| GSK Investigational Site | Greenville | North Carolina | 27834 | — |
| GSK Investigational Site | Dayton | Ohio | 46432 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Medford | Oregon | 97504-8456 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Columbia | South Carolina | 29201 | — |
| GSK Investigational Site | Dallas | Texas | 75213 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
| GSK Investigational Site | Walla Walla | Washington | 99362 | — |
| GSK Investigational Site | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00256854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2019 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00256854 live on ClinicalTrials.gov.